Johnson & Johnson’s (J&J) is expected to seek US approval next year for a new anti wrinkle drug that would serve as the stand-alone competitor to Botox. The company said the product could be made available in 2015 in the United States. The anti wrinkle drug market enjoys annual revenue of almost $900 million (R8,3 […]